|1.||Goldenberg, David M: 12 articles (02/2015 - 05/2002)|
|2.||Lum, Lawrence G: 10 articles (11/2015 - 01/2004)|
|3.||Baeuerle, Patrick A: 9 articles (06/2013 - 08/2003)|
|4.||Lindhofer, Horst: 8 articles (08/2015 - 11/2005)|
|5.||Asano, Ryutaro: 8 articles (01/2015 - 03/2002)|
|6.||Ruf, Peter: 6 articles (08/2015 - 09/2008)|
|7.||Sharkey, Robert M: 6 articles (02/2015 - 05/2002)|
|8.||Kumagai, Izumi: 6 articles (01/2015 - 03/2002)|
|9.||Cartellieri, Marc: 6 articles (09/2014 - 06/2011)|
|10.||Feldmann, Anja: 6 articles (09/2014 - 06/2011)|
09/01/1997 - "Designed to direct and enhance the body's immune response to specific tumours and pathogens, bispecific antibodies have shown promising results in Phase I and Phase II clinical trials, leading in some cases to complete or partial responses in cancer patients. "
03/01/2014 - "Various constructs of bispecific antibodies (bsAbs) to redirect effector T cells for the targeted killing of tumor cells have shown considerable promise in both preclinical and clinical studies. "
03/01/2015 - "T-cell retargeting bispecific antibodies (BsAb) also have clinical potential, but it is thus far only effective against liquid tumors. "
03/08/2002 - "A number of bispecific antibodies against B-cell markers have been shown to be effective in vitro in mediating tumor cell lysis and in vivo in inhibiting tumor growth in animal models. "
01/01/2011 - "Humanized mice were generated in order to investigate the anti-tumor efficacy of bispecific antibodies. "
|2.||Hematologic Neoplasms (Hematological Malignancy)
01/01/2015 - "Bispecific antibodies (bsAbs) engaging T cells are emerging as a promising immunotherapeutic tool for the treatment of hematologic malignancies. "
09/01/2008 - "This review provides a preclinical and clinical perspective on application of bispecific antibodies for the treatment of solid tumors, hematologic malignancies and other diseases. "
01/01/2001 - "Bispecific monoclonal antibodies for the targeting of type I ribosome-inactivating proteins against hematological malignancies."
01/10/2015 - "Recently conducted clinical trials have provided impressive evidence that chemotherapy resistant metastatic melanoma and several hematological malignancies can be cured using adoptive T cell therapy or T cell-recruiting bispecific antibodies. "
11/01/2015 - "Various methods for manipulating the immune system including check-point inhibitors, chimeric antigen receptor T cells, and bispecific antibodies have shown promising activity in treating both hematological malignancies and solid tumors with excellent success. "
10/01/1995 - "In vivo studies using bispecific antibodies (anti-CD3 x anti-idiotype) and CD28-induced costimulation in the BCL1 lymphoma."
03/01/2002 - "Bispecific antibodies for lymphoma are also in early clinical testing. "
09/01/2000 - "Bispecific antibodies for lymphoma may also have a future role in lymphoma therapy. "
05/01/2000 - "Alternatively, bispecific antibodies and idiotypic vaccination strategies are used to target autologous T cells to eliminate lymphoma cells. "
12/15/1998 - "These polyclonal CTLs, targeted by the CD3x19 bispecific antibodies, can lyse CD19(+) B-lymphoma cells. "
|4.||Hodgkin Disease (Hodgkin's Disease)
04/01/2013 - "Rescue of impaired NK cell activity in hodgkin lymphoma with bispecific antibodies in vitro and in patients."
07/01/2001 - "Treating Hodgkin's disease with bispecific antibodies: Both patients and antibody are limiting."
01/01/2000 - "Immune recruitment by bispecific antibodies for the treatment of Hodgkin disease."
10/01/1998 - "Anti-CD16/CD30 bispecific antibodies as possible treatment for refractory Hodgkin's disease."
01/01/1996 - "Treatment of Hodgkin's disease with bispecific antibodies."
07/01/2000 - "Bispecific antibodies (bsAb) are considered as promising tools for the elimination of disseminated tumour cells in a minimal residual disease situation. "
06/01/2003 - "Bispecific antibodies (BsAb) with specificity to both tumor cells and CD3 molecule were believed to be promising immunological tools for the therapy with minimal residual diseases by activating cytotoxic T cells. "
10/15/2001 - "Bispecific antibodies (bsAbs) can efficiently mediate tumor cell killing by redirecting preactivated or costimulated T cells to disseminated tumor cells, especially in a minimal residual disease situation. "
07/01/2001 - "Bispecific monoclonal antibodies (bsAbs) are a promising immunotherapeutic option for treatment of cancer, especially in situations of minimal residual disease. "
02/15/2006 - "Trifunctional bispecific antibodies (TbsAbs) capable of cross-linking T lymphocytes, natural killer, and other FcgammaR-positive effector cells, via their Fc region, to the tumor cells may be applied together with adoptive allogeneic-cell therapy to maximize antitumor responses while acting on GVHD in patients with minimal residual disease."
|4.||Immunoglobulin G (IgG)
|5.||T-Cell Antigen Receptors (T-Cell Receptor)
|6.||IgG Receptors (Fc gamma RI)
|8.||Complement System Proteins (Complement)
|10.||Antigen Receptors (Antigen Receptor)
|3.||Drug Therapy (Chemotherapy)
|4.||Tissue Therapy (Cell Therapy)
|5.||Heterologous Transplantation (Xenotransplantation)